Seladelpar Lysine is a small molecule commercialized by CymaBay Therapeutics, with a leading Phase III program in Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to Globaldata, it is involved in 14 clinical trials, of which 9 were completed, 3 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Seladelpar Lysine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Seladelpar Lysine is expected to reach an annual total of $379 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Seladelpar Lysine Overview

Seladelpar lysine (MBX-8025, RWJ-800025) is under development for the treatment of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC). The drug candidate is administered through the oral route as a capsule. MBX-8025 targets human PPAR-delta receptor. It was under development for the treatment of Fredrickson types I and V hyperlipoproteinemias, non-alcoholic steatohepatitis (NASH), mixed dyslipidemia, severe hypertriglyceridemia (SHTG) and homozygous familial hypercholesterolemia (HoFH).

CymaBay Therapeutics Overview

CymaBay Therapeutics (CymaBay), formerly Metabolex is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, liver and other chronic diseases, orphan diseases, and related metabolic disorders. The company’s pipeline products comprise Seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd) for the treatment of liver diseases. It also develops MBX-2982 for patients with type 1 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

The operating loss of the company was US$87.6 million in FY2021, compared to an operating loss of US$52.6 million in FY2020. The net loss of the company was US$90 million in FY2021, compared to a net loss of US$51 million in FY2020.

For a complete picture of Seladelpar Lysine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.